Simms Christopher Paul
- SEC CIK
- 0001877012
No open-market purchases or sales filed in the past year.
Current role at each company
- FDMT 4D Molecular Therapeutics, Inc.See Remarksas of Mar 27, 2026
- ISEE IVERIC bio, Inc.SVP, Chief Commercial Officeras of Jul 13, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Simms Christopher Paul as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ISEE IVERIC bio, Inc.
SVP, Chief Commercial Officer3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Simms Christopher PaulSVP, Chief Commercial Officer | SSale | −2.37K | $20.06 | −$47.5K | −6.8%32.4K after | |
| Aug 4, 2022 (view filing) | Aug 3 | 1 day | Simms Christopher PaulSVP, Chief Commercial Officer | SSale | −12.3K | $11.25 | −$138.1K | −30.1%28.5K after | 2 lots |
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Simms Christopher PaulSVP, Chief Commercial Officer | PPurchase | +3.07K | $16.30 | +$50.0K | +76.7%7.07K after |